Wednesday - January 8, 2025
CARMEL, Ind., Oct. 1, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, is celebrating its first anniversary as a publicly traded company and highlighting its many successes. This milestone not only marks the Company's growth but also reflects its unwavering commitment to transforming healthcare service. As the Company highlights significant achievements over the past year, it remains focused on its mission to become a leader in healthcare solutions, empowering communities and improving health outcomes across the nation.
"It's exciting to look back on what the Syra Health team has achieved over the past year since our Nasdaq listing," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We have increased our revenues and are strategically taking actions to reduce operating expenses. We are expanding our impact across various geographies and business units, always with a focus on making a real difference in the communities we serve. By focusing on our high-margin areas, we have not only boosted our profit margins but also continued to invest in innovative solutions that will shape the future of healthcare. Our legacy business unit, Healthcare Workforce, remains the cornerstone that fuels these advancements, allowing us to push boundaries and improve health outcomes every step of the way."
Syra Health's achievements since the Company's 2023 IPO:
"From a financial standpoint, we have significantly increased our revenues over the past year while actively working to reduce our operating expenses and increase operational efficiencies," said Priya Prasad, CFO, Syra Health. "Our team is dedicated to delivering innovative healthcare solutions, whether through services or technology products. We are committed to improving health and progressing on our journey to profitability."
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology products. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts
For Media or Investor Inquiries:
Christine Drury
PR/IR and Marketing Director
Syra Health
463-345-5180
christined@syrahealth.com
Last Trade: | US$0.70 |
Daily Change: | 0.21 43.24 |
Daily Volume: | 522,840,442 |
Market Cap: | US$6.300M |
December 02, 2024 November 26, 2024 October 29, 2024 September 13, 2024 August 08, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load